Stifel Financial
GMAB icon

Stifel Financial’s Genmab GMAB Stock Holding History

Stifel Financial’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6M Sell
58,237
-20,868
-26% -$555K ﹤0.01% 2239
2026
Q1 		$2.12M Buy
79,105
+39,174
+98% +$1.17M ﹤0.01% 1925
2025
Q4 		$1.23M Buy
39,931
+17,510
+78% +$546K ﹤0.01% 2301
2025
Q3 		$688K Sell
22,421
-327
-1% -$7.97K ﹤0.01% 2616
2025
Q2 		$470K Sell
22,748
-40,306
-64% -$827K ﹤0.01% 2815
2025
Q1 		$1.23M Sell
63,054
-45,121
-42% -$946K ﹤0.01% 2098
2024
Q4 		$2.26M Sell
108,175
-60,816
-36% -$1.34M ﹤0.01% 1694
2024
Q3 		$4.12M Sell
168,991
-5,936
-3% -$159K ﹤0.01% 1309
2024
Q2 		$4.4M Sell
174,927
-58,001
-25% -$1.64M ﹤0.01% 1219
2024
Q1 		$6.97M Sell
232,928
-439,965
-65% -$12.9M 0.01% 963
2023
Q4 		$21.4M Sell
672,893
-35,216
-5% -$1.11M 0.03% 489
2023
Q3 		$25M Sell
708,109
-21,415
-3% -$816K 0.04% 414
2023
Q2 		$27.7M Sell
729,524
-10,573
-1% -$422K 0.04% 380
2023
Q1 		$27.9M Buy
740,097
+3,547
+0.5% +$136K 0.04% 375
2022
Q4 		$31.2M Sell
736,550
-1,041
-0.1% -$42.9K 0.05% 339
2022
Q3 		$23.7M Buy
737,591
+20,346
+3% +$714K 0.04% 387
2022
Q2 		$23.3M Sell
717,245
-435,845
-38% -$14.1M 0.04% 396
2022
Q1 		$41.7M Sell
1,153,090
-56,333
-5% -$1.93M 0.06% 284
2021
Q4 		$47.8M Buy
1,209,423
+12,587
+1% +$525K 0.06% 261
2021
Q3 		$52.3M Buy
1,196,836
+42,948
+4% +$1.93M 0.08% 244
2021
Q2 		$47.1M Buy
1,153,888
+15,729
+1% +$607K 0.07% 254
2021
Q1 		$37.4M Sell
1,138,159
-111,519
-9% -$4.19M 0.06% 276
2020
Q4 		$50.8M Buy
1,249,678
+136,541
+12% +$5.1M 0.09% 220
2020
Q3 		$40.8M Buy
1,113,137
+161,507
+17% +$5.84M 0.08% 224
2020
Q2 		$32.3M Buy
951,630
+852,540
+860% +$23.2M 0.07% 246
2020
Q1 		$2.17M Buy
99,090
+2,247
+2% +$50.1K 0.01% 1008
2019
Q4 		$2.21M Buy
96,843
+1,654
+2% +$36.1K ﹤0.01% 1274
2019
Q3 		$1.99M Buy
+95,189
New +$1.87M 0.01% 1318

Other funds holding GMAB

PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Stifel Financial's GMAB Position: Q2 2026 in Review

Stifel Financial reduced its Genmab (GMAB) stake by 26% in Q2 2026, selling an estimated $555K and leaving 58,237 shares worth $1.6M. The position accounts for ﹤0.01% of the portfolio, ranked #2239.

Stifel Financial first reported a position in GMAB in Q3 2019 and has held it in 28 quarters since. The position peaked at $52.3M in Q3 2021. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

  • Stifel Financial held 58,237 shares of Genmab worth $1.6M as of Q2 2026.
  • Stifel Financial sold 20,868 Genmab shares in Q2 2026, an estimated $555K.
  • Genmab made up ﹤0.01% of Stifel Financial's portfolio in Q2 2026, its #2239 holding.
  • Stifel Financial first reported a position in Genmab in Q3 2019 and has held it in 28 quarters since.
  • Stifel Financial's Genmab position peaked at $52.3M in Q3 2021.
  • 289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.